Acrivon director granted 20,275 stock options

Acrivon Therapeutics, Inc. director Sharon Shacham received a grant of stock options representing 20,275 shares of common stock.

Rhea-AI Filing Summary

Acrivon Therapeutics, Inc. director Sharon Shacham received a grant of stock options representing 20,275 shares of common stock. The options have an exercise price of $1.52 per share and expire on June 16, 2036.

All 20,275 option shares remain held following the transaction. According to the grant terms, these options vest on the date immediately preceding Acrivon’s next annual meeting of stockholders, provided Shacham continues to serve through that vesting date.

Insider Trade Summary

Grant/Award: 20,275 shares

Grant/Award 1 txn

Insider Shacham Sharon

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	20,275	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 20,275 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date.

Key Figures

Options granted: 20,275 options Exercise price: $1.52 per share Expiration date: June 16, 2036 +2 more

5 metrics

Options granted 20,275 options Stock Option (Right to Buy) grant to director Sharon Shacham

Exercise price $1.52 per share Exercise price of options on Acrivon common stock

Expiration date June 16, 2036 Option expiration for 20,275-share grant

Shares underlying options 20,275 shares Underlying Acrivon common stock tied to option grant

Total options held after grant 20,275 options Total derivative securities following this transaction

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, derivative security, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "1.5200""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-06-16T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

derivative security financial

"transaction_type: "derivative""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

vesting financial

"options shall vest on the date immediately preceding the date of the Issuer's next annual meeting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Acrivon Therapeutics (ACRV) director Sharon Shacham report on this Form 4?

Sharon Shacham reported receiving a grant of stock options for 20,275 shares of Acrivon Therapeutics common stock. These options were awarded as compensation and are documented as a derivative security labeled “Stock Option (Right to Buy)” tied to the company’s common stock.

What are the key terms of Sharon Shacham’s ACRV stock option grant?

The grant covers 20,275 underlying shares at an exercise price of $1.52 per share, expiring on June 16, 2036. All 20,275 options are held directly following the transaction, reflecting a compensation-related award rather than an open-market stock purchase or sale.

When do Sharon Shacham’s Acrivon Therapeutics options vest?

The options vest on the date immediately preceding Acrivon Therapeutics’ next annual meeting of stockholders. Vesting is conditional on Sharon Shacham’s continuous service with the company through that vesting date, as specified in the footnote to the Form 4 filing.

Did Sharon Shacham buy or sell ACRV shares in the open market?

No open-market buy or sell occurred. The Form 4 shows a grant classified as a derivative acquisition, with transaction code A for an award of stock options. The transaction price per option is reported as $0.00, indicating a compensation grant, not a market trade.

How many ACRV-related derivative securities does Sharon Shacham hold after this transaction?

After this grant, Sharon Shacham holds 20,275 stock options linked to Acrivon Therapeutics common stock. The reported total shares following the transaction correspond to the full amount of the new award, reflecting her current derivative position in this option grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 04:13 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shacham Sharon

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.52	06/17/2026		A		20,275		(1)	06/16/2036	Common Stock	20,275	$0	20,275	D

Explanation of Responses:

1. The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date.

	/s/ Adam D. Levy, Attorney-in-Fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)